CJC-1295 (without DAC) vs Rapamycin
Well Studied vs FDA Approved
monitor Mechanism-based · 47% Both CJC-1295 (without DAC) and Rapamycin affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
CJC-1295 (without DAC) Rapamycin
Weight 3,367.97 Da 914.17 Da
Half-life 30 minutes - 2 hours ~62 hours
Chain 30 amino acids —
Type GHRH analog Macrolide lactone (C51H79NO13)
Key Benefits
CJC-1295 (without DAC)
01 Preserves natural GH pulsatility
02 Minimal side effects
03 No receptor desensitization
04 Precise GH release control
05 4x greater receptor affinity than native GHRH
Rapamycin
01 Lifespan extension demonstrated in every model organism tested (yeast, worms, flies, mice)
02 Upregulation of autophagy and cellular quality control mechanisms
03 Reduction of senescent cell burden and associated inflammatory secretome
04 Improved immune function at low pulsed doses (paradoxical immune enhancement)
05 Reduced age-related inflammation (inflammaging) via mTORC1 inhibition
06 Enhanced mitochondrial function and biogenesis
07 Potential reduction in age-related cancer risk through growth pathway suppression
08 Improved vaccine response in elderly populations at low intermittent doses
Dosing Protocols
CJC-1295 (without DAC)
100-300mcg per injection / 2-3 times daily (morning, post-workout optional, bedtime)
Anti-Aging/Wellness 100mcg 2x daily (morning and bedtime)
Body Composition 100-150mcg 3x daily (morning, post-workout, bedtime)
Maximum GH Release 200mcg 2-3x daily with GHRP
Sleep Enhancement 100-200mcg Once at bedtime
Rapamycin
3-6 mg once weekly (longevity protocol) / Once weekly (pulsed longevity) or daily (immunosuppressive)
Side Effects
CJC-1295 (without DAC)
Generally well-tolerated at recommended doses
Temporary facial flushing/warmth (5-10 minutes post-injection)
Rapamycin
Mouth sores / aphthous ulcers (most common, usually dose-dependent and self-limiting)
Mild lipid changes (elevated LDL cholesterol and triglycerides)
Temporary glucose elevation or mildly impaired fasting glucose
Mild gastrointestinal discomfort (nausea, loose stools)
Skin changes (mild acne, slower wound healing at injection/cut sites)
Contraindications
Active cancer (due to growth-promoting effects)
Diabetic retinopathy
Severe kidney disease
Pregnancy or breastfeeding
Active serious infection or immunocompromised state
Hypersensitivity to rapamycin/sirolimus or any macrolide compound
Severe hepatic impairment (rapamycin is extensively hepatically metabolized)
Planned major surgery within 2-4 weeks (impaired wound healing)
Pregnancy or breastfeeding
Concurrent use of strong CYP3A4 inhibitors without dose adjustment (ketoconazole, itraconazole, clarithromycin, grapefruit juice)
Research Evidence
CJC-1295 (without DAC) Rapamycin
Status Well Studied FDA Approved
References 5 studies 5 studies
Latest November 2024 March 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.